Literature DB >> 7836928

Class II transactivator regulates the expression of multiple genes involved in antigen presentation.

C H Chang1, R A Flavell.   

Abstract

CIITA (a major histocompatibility complex [MHC] class II transactivator) has been shown to be required for the expression of MHC class II genes in both B cells and interferon gamma-inducible cells. Here we demonstrate that CIITA not only activates MHC class II genes but also genes required for antigen presentation. Mutant HeLa cells, defective in the expression of classic MHC class II genes, invariant chain, and the newly described human histocompatibility leukocyte antigen-DM genes, were used to study the role of CIITA in the regulation of these genes. Upon transfection with CIITA cDNA, the mutant cells expressed all three genes, suggesting that CIITA is a global regulator for the expression of genes involved in antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836928      PMCID: PMC2191893          DOI: 10.1084/jem.181.2.765

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  A new human HLA class II-related locus, DM.

Authors:  A P Kelly; J J Monaco; S G Cho; J Trowsdale
Journal:  Nature       Date:  1991-10-10       Impact factor: 49.962

Review 2.  Sequences and factors: a guide to MHC class-II transcription.

Authors:  L H Glimcher; C J Kara
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).

Authors:  V Steimle; L A Otten; M Zufferey; B Mach
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

Review 4.  Antigen presentation. Getting peptides into MHC class II molecules.

Authors:  P Cresswell
Journal:  Curr Biol       Date:  1994-06-01       Impact factor: 10.834

5.  Mutant cell lines unresponsive to alpha/beta and gamma interferon are defective in tyrosine phosphorylation of ISGF-3 alpha components.

Authors:  J E Loh; C Schindler; A Ziemiecki; A G Harpur; A F Wilks; R A Flavell
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

6.  HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells.

Authors:  S P Fling; B Arp; D Pious
Journal:  Nature       Date:  1994-04-07       Impact factor: 49.962

7.  An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules.

Authors:  P Morris; J Shaman; M Attaya; M Amaya; S Goodman; C Bergman; J J Monaco; E Mellins
Journal:  Nature       Date:  1994-04-07       Impact factor: 49.962

8.  Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

Authors:  V Steimle; C A Siegrist; A Mottet; B Lisowska-Grospierre; B Mach
Journal:  Science       Date:  1994-07-01       Impact factor: 47.728

9.  Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s).

Authors:  J E Loh; C H Chang; W L Fodor; R A Flavell
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

10.  Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.

Authors:  C H Chang; J D Fontes; M Peterlin; R A Flavell
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

  10 in total
  64 in total

Review 1.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.

Authors:  Krzysztof Masternak; Walter Reith
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

3.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

4.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

5.  Cell contact-dependent PMN HLA-DR and CD69 membrane expression induced by autologous mono-lymphocytes and cell lines.

Authors:  A Vella; S Sartoris; L Bambara; R Ortolani; A Carletto; D Biasi; E Stefani; G Tridente
Journal:  Inflammation       Date:  2002-08       Impact factor: 4.092

Review 6.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 7.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

8.  Role of Sug1, a 19S proteasome ATPase, in the transcription of MHC I and the atypical MHC II molecules, HLA-DM and HLA-DO.

Authors:  Yaritza Inostroza-Nieves; Prasanna Venkatraman; Zarixia Zavala-Ruiz
Journal:  Immunol Lett       Date:  2012-07-04       Impact factor: 3.685

Review 9.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

Review 10.  The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association.

Authors:  P G Bronson; L A Criswell; L F Barcellos
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.